Amneal Capex To Revenue vs Ebit Per Revenue Analysis

AMRX Stock

USD 8.53 0.04 0.47%

Amneal Pharmaceuticals, financial indicator trend analysis is way more than just evaluating Amneal Pharmaceuticals, prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Amneal Pharmaceuticals, is a good investment. Please check the relationship between Amneal Pharmaceuticals, Capex To Revenue and its Ebit Per Revenue accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Amneal Pharmaceuticals, Class. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

Capex To Revenue vs Ebit Per Revenue

Capex To Revenue vs Ebit Per Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Amneal Pharmaceuticals, Capex To Revenue account and Ebit Per Revenue. At this time, the significance of the direction appears to have strong relationship.

The correlation between Amneal Pharmaceuticals,'s Capex To Revenue and Ebit Per Revenue is 0.76. Overlapping area represents the amount of variation of Capex To Revenue that can explain the historical movement of Ebit Per Revenue in the same time period over historical financial statements of Amneal Pharmaceuticals, Class, assuming nothing else is changed. The correlation between historical values of Amneal Pharmaceuticals,'s Capex To Revenue and Ebit Per Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capex To Revenue of Amneal Pharmaceuticals, Class are associated (or correlated) with its Ebit Per Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Ebit Per Revenue has no effect on the direction of Capex To Revenue i.e., Amneal Pharmaceuticals,'s Capex To Revenue and Ebit Per Revenue go up and down completely randomly.

Correlation Coefficient

0.76

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Capex To Revenue

The ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets.

Ebit Per Revenue

Most indicators from Amneal Pharmaceuticals,'s fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Amneal Pharmaceuticals, current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Amneal Pharmaceuticals, Class. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

At this time, Amneal Pharmaceuticals,'s Enterprise Value Over EBITDA is fairly stable compared to the past year. Enterprise Value Multiple is likely to rise to 7.82 in 2024, whereas Selling General Administrative is likely to drop slightly above 281.2 M in 2024.

	2021	2022	2023	2024 (projected)
Gross Profit	769.0M	784.7M	820.6M	675.9M
Total Revenue	2.1B	2.2B	2.4B	1.7B

Gross Profit Total Revenue

Amneal Pharmaceuticals, fundamental ratios Correlations

	Total Assets	Common Stock Shares Outstanding	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Net Receivables	Good Will	Short Term Investments	Long Term Debt Total	Non Current Liabilities Total	Capital Surpluse	Inventory	Other Current Assets	Other Stockholder Equity
Total Assets		0.42	0.44	0.88	0.88	0.76	-0.95	0.83	0.89	-0.28	0.69	0.71	0.96	0.82	0.61	0.91	0.69	0.84	0.93	-0.78	0.93	0.94	0.65	0.87	0.92	0.94
Common Stock Shares Outstanding	0.42		0.45	0.69	0.39	0.43	-0.61	0.65	0.65	-0.5	0.27	0.36	0.6	0.6	0.24	0.65	0.35	0.67	0.67	-0.62	0.66	0.64	0.68	0.69	0.59	0.62
Other Current Liab	0.44	0.45		0.66	0.14	0.14	-0.38	0.42	0.43	-0.45	-0.29	0.29	0.37	0.31	0.17	0.42	0.29	0.61	0.64	-0.3	0.49	0.45	0.71	0.65	0.48	0.49
Total Current Liabilities	0.88	0.69	0.66		0.65	0.67	-0.91	0.89	0.94	-0.61	0.45	0.54	0.89	0.87	0.4	0.93	0.53	0.94	0.99	-0.83	0.96	0.93	0.92	0.99	0.88	0.93
Total Stockholder Equity	0.88	0.39	0.14	0.65		0.83	-0.85	0.69	0.73	0.1	0.82	0.71	0.9	0.66	0.77	0.79	0.7	0.64	0.74	-0.64	0.8	0.83	0.33	0.68	0.86	0.8
Other Liab	0.76	0.43	0.14	0.67	0.83		-0.74	0.6	0.7	-0.01	0.68	0.49	0.81	0.69	0.6	0.72	0.48	0.55	0.68	-0.57	0.73	0.74	0.43	0.73	0.82	0.65
Net Tangible Assets	-0.95	-0.61	-0.38	-0.91	-0.85	-0.74		-0.94	-0.96	0.43	-0.74	-0.71	-0.99	-0.91	-0.54	-0.98	-0.69	-0.91	-0.94	0.9	-0.97	-0.99	-0.71	-0.9	-0.91	-0.98
Property Plant And Equipment Net	0.83	0.65	0.42	0.89	0.69	0.6	-0.94		0.97	-0.58	0.58	0.64	0.91	0.93	0.49	0.98	0.63	0.96	0.91	-0.98	0.94	0.96	0.78	0.89	0.85	0.94
Net Debt	0.89	0.65	0.43	0.94	0.73	0.7	-0.96	0.97		-0.57	0.62	0.62	0.95	0.97	0.48	0.99	0.61	0.94	0.95	-0.96	0.97	0.98	0.81	0.94	0.89	0.96
Retained Earnings	-0.28	-0.5	-0.45	-0.61	0.1	-0.01	0.43	-0.58	-0.57		-0.02	-0.03	-0.33	-0.58	0.31	-0.5	-0.02	-0.63	-0.52	0.6	-0.49	-0.45	-0.81	-0.57	-0.27	-0.49
Accounts Payable	0.69	0.27	-0.29	0.45	0.82	0.68	-0.74	0.58	0.62	-0.02		0.45	0.75	0.61	0.43	0.65	0.44	0.46	0.52	-0.59	0.65	0.67	0.2	0.45	0.61	0.65
Cash	0.71	0.36	0.29	0.54	0.71	0.49	-0.71	0.64	0.62	-0.03	0.45		0.7	0.58	0.69	0.68	1.0	0.56	0.61	-0.62	0.65	0.7	0.3	0.55	0.59	0.66
Non Current Assets Total	0.96	0.6	0.37	0.89	0.9	0.81	-0.99	0.91	0.95	-0.33	0.75	0.7		0.89	0.61	0.97	0.68	0.89	0.94	-0.87	0.97	0.98	0.68	0.9	0.95	0.97
Non Currrent Assets Other	0.82	0.6	0.31	0.87	0.66	0.69	-0.91	0.93	0.97	-0.58	0.61	0.58	0.89		0.44	0.94	0.56	0.87	0.86	-0.96	0.89	0.92	0.74	0.87	0.83	0.88
Other Assets	0.61	0.24	0.17	0.4	0.77	0.6	-0.54	0.49	0.48	0.31	0.43	0.69	0.61	0.44		0.53	0.68	0.37	0.5	-0.45	0.51	0.56	0.14	0.45	0.7	0.48
Long Term Debt	0.91	0.65	0.42	0.93	0.79	0.72	-0.98	0.98	0.99	-0.5	0.65	0.68	0.97	0.94	0.53		0.66	0.95	0.95	-0.95	0.98	0.99	0.78	0.93	0.91	0.97
Cash And Short Term Investments	0.69	0.35	0.29	0.53	0.7	0.48	-0.69	0.63	0.61	-0.02	0.44	1.0	0.68	0.56	0.68	0.66		0.55	0.59	-0.6	0.63	0.69	0.28	0.54	0.58	0.64
Net Receivables	0.84	0.67	0.61	0.94	0.64	0.55	-0.91	0.96	0.94	-0.63	0.46	0.56	0.89	0.87	0.37	0.95	0.55		0.95	-0.9	0.94	0.95	0.86	0.93	0.85	0.95
Good Will	0.93	0.67	0.64	0.99	0.74	0.68	-0.94	0.91	0.95	-0.52	0.52	0.61	0.94	0.86	0.5	0.95	0.59	0.95		-0.84	0.98	0.96	0.86	0.98	0.93	0.97
Short Term Investments	-0.78	-0.62	-0.3	-0.83	-0.64	-0.57	0.9	-0.98	-0.96	0.6	-0.59	-0.62	-0.87	-0.96	-0.45	-0.95	-0.6	-0.9	-0.84		-0.89	-0.92	-0.73	-0.83	-0.79	-0.88
Long Term Debt Total	0.93	0.66	0.49	0.96	0.8	0.73	-0.97	0.94	0.97	-0.49	0.65	0.65	0.97	0.89	0.51	0.98	0.63	0.94	0.98	-0.89		0.98	0.82	0.96	0.92	0.98
Non Current Liabilities Total	0.94	0.64	0.45	0.93	0.83	0.74	-0.99	0.96	0.98	-0.45	0.67	0.7	0.98	0.92	0.56	0.99	0.69	0.95	0.96	-0.92	0.98		0.76	0.93	0.93	0.98
Capital Surpluse	0.65	0.68	0.71	0.92	0.33	0.43	-0.71	0.78	0.81	-0.81	0.2	0.3	0.68	0.74	0.14	0.78	0.28	0.86	0.86	-0.73	0.82	0.76		0.9	0.68	0.77
Inventory	0.87	0.69	0.65	0.99	0.68	0.73	-0.9	0.89	0.94	-0.57	0.45	0.55	0.9	0.87	0.45	0.93	0.54	0.93	0.98	-0.83	0.96	0.93	0.9		0.91	0.91
Other Current Assets	0.92	0.59	0.48	0.88	0.86	0.82	-0.91	0.85	0.89	-0.27	0.61	0.59	0.95	0.83	0.7	0.91	0.58	0.85	0.93	-0.79	0.92	0.93	0.68	0.91		0.9
Other Stockholder Equity	0.94	0.62	0.49	0.93	0.8	0.65	-0.98	0.94	0.96	-0.49	0.65	0.66	0.97	0.88	0.48	0.97	0.64	0.95	0.97	-0.88	0.98	0.98	0.77	0.91	0.9

Click cells to compare fundamentals

Amneal Pharmaceuticals, Account Relationship Matchups

Amneal Pharmaceuticals, fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	3.7B	4.0B	3.9B	3.8B	3.5B	3.2B
Common Stock Shares Outstanding	132.1M	148.9M	151.8M	150.9M	176.1M	151.5M
Other Current Liab	6.0M	459.8M	495.8M	481.0M	475.4M	275.3M
Total Current Liabilities	550.4M	676.9M	677.2M	752.8M	846.6M	589.0M
Total Stockholder Equity	346.8M	344.9M	367.0M	184.0M	19.8M	18.8M
Other Liab	35.7M	87.3M	48.5M	97.1M	111.7M	75.0M
Net Tangible Assets	(1.6B)	(1.5B)	(1.4B)	(1.4B)	(1.2B)	(1.3B)
Property Plant And Equipment Net	609.2M	595.2M	639.0M	589.4M	550.1M	579.3M
Net Debt	2.6B	2.6B	2.6B	2.8B	2.7B	2.1B
Retained Earnings	(377.9M)	(286.8M)	(276.2M)	(406.2M)	(490.2M)	(465.7M)
Accounts Payable	507.5M	154.1M	132.9M	166.8M	143.6M	222.4M
Cash	151.2M	341.4M	247.8M	26.0M	91.5M	150.8M
Non Current Assets Total	2.5B	2.5B	2.4B	2.4B	2.1B	2.0B
Non Currrent Assets Other	44.3M	31.9M	20.6M	103.2M	18.4M	19.3M
Other Assets	16.5M	149.3M	473.7M	17.6M	20.3M	19.3M
Long Term Debt	2.6B	2.7B	2.7B	2.6B	2.4B	2.2B
Cash And Short Term Investments	151.2M	341.4M	247.8M	26.0M	91.5M	152.0M
Net Receivables	606.2M	674.2M	662.6M	741.8M	613.7M	590.6M
Good Will	419.5M	522.8M	593.0M	598.9M	598.6M	396.5M
Short Term Investments	1.1M	1.7M	1.2M	1.8M	2.2M	1.9M
Long Term Debt Total	2.7B	2.7B	2.7B	2.6B	3.0B	2.1B
Non Current Liabilities Total	2.8B	3.0B	2.9B	2.8B	2.6B	2.5B
Capital Surpluse	607.0M	628.4M	658.4M	691.6M	795.4M	648.3M
Inventory	381.1M	490.6M	489.4M	530.7M	581.4M	454.1M
Other Current Assets	70.2M	80.5M	120.3M	113.3M	91.2M	85.3M
Other Stockholder Equity	721.7M	670.1M	658.4M	691.6M	539.2M	463.4M
Total Liab	3.3B	3.7B	3.6B	3.6B	3.5B	3.1B
Short Long Term Debt	21.5M	45.2M	30.6M	90.0M	213.1M	223.8M
Total Current Assets	1.2B	1.6B	1.5B	1.4B	1.4B	1.3B
Short Term Debt	37.0M	57.5M	46.0M	104.6M	227.6M	239.0M
Intangible Assets	1.4B	1.3B	1.2B	1.1B	890.4M	933.3M
Common Stock	3.0M	3.0M	3.0M	3.0M	3.1M	3.2M
Property Plant Equipment	620.6M	477.8M	514.2M	469.8M	540.3M	513.5M
Short Long Term Debt Total	2.8B	2.9B	2.9B	2.8B	2.8B	2.9B
Noncontrolling Interest In Consolidated Entity	114.8M	41.7M	6.6M	(114.4M)	(103.0M)	(97.8M)
Common Stock Total Equity	3.0M	3.0M	3.0M	3.0M	3.5M	2.8M
Retained Earnings Total Equity	(377.9M)	(286.8M)	(276.2M)	(406.2M)	(365.6M)	(347.3M)
Liabilities And Stockholders Equity	3.7B	4.0B	3.9B	3.8B	3.5B	3.9B
Capital Lease Obligations	135.5M	123.9M	127.4M	123.5M	109.9M	110.0M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

TITAN	Titan Company Limited
U	Unity Software
PAYC	Paycom Soft

Additional Tools for Amneal Stock Analysis

When running Amneal Pharmaceuticals,'s price analysis, check to measure Amneal Pharmaceuticals,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amneal Pharmaceuticals, is operating at the current time. Most of Amneal Pharmaceuticals,'s value examination focuses on studying past and present price action to predict the probability of Amneal Pharmaceuticals,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amneal Pharmaceuticals,'s price. Additionally, you may evaluate how the addition of Amneal Pharmaceuticals, to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Amneal Capex To Revenue vs Ebit Per Revenue Analysis

Capex To Revenue vs Ebit Per Revenue

Capex To Revenue vs Ebit Per Revenue Correlation Analysis

Correlation Coefficient

Capex To Revenue

Ebit Per Revenue

Amneal Pharmaceuticals, fundamental ratios Correlations

Amneal Pharmaceuticals, Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Amneal Pharmaceuticals, fundamental ratios Accounts

Also Currently Popular

Additional Tools for Amneal Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Cash
Good Will	+ 0.99	Total Current Liabilities
Inventory	+ 0.99	Total Current Liabilities
Long Term Debt	+ 0.99	Net Debt
Non Current Liabilities Total	+ 0.99	Long Term Debt
Long Term Debt	+ 0.98	Property Plant And Equipment Net

Non Current Liabilities Total	- 0.99	Net Tangible Assets
Non Current Assets Total	- 0.99	Net Tangible Assets
Short Term Investments	- 0.98	Property Plant And Equipment Net
Other Stockholder Equity	- 0.98	Net Tangible Assets
Long Term Debt	- 0.98	Net Tangible Assets
Long Term Debt Total	- 0.97	Net Tangible Assets